**Core Concept**
Ondansetron is a medication used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Its mechanism of action is related to the regulation of neurotransmitter release in the central nervous system.

**Why the Correct Answer is Right**
Ondansetron acts by selectively blocking the action of serotonin (5-HT3) at the 5-HT3 receptor, a subtype of serotonin receptor. This receptor is located in the central nervous system and the gastrointestinal tract, and its stimulation is thought to be responsible for the initiation of vomiting. By blocking the 5-HT3 receptor, ondansetron prevents the release of other neurotransmitters, such as substance P, which are involved in the vomiting reflex.

**Why Each Wrong Option is Incorrect**
**Option A:** RANK ligand inhibitor - RANKL (Receptor Activator of NF-κB Ligand) is a protein involved in the formation, function, and survival of osteoclasts, and is not related to the mechanism of action of ondansetron.
**Option B:** MMDA antagonist - MMDA (N-methyl-D-aspartate) is a type of glutamate receptor, and antagonists of this receptor are used in the treatment of certain neurological disorders, but are not involved in the mechanism of action of ondansetron.
**Option C:** NK 1 receptor antagonist - NK1 receptors are involved in the transmission of pain and are targeted by certain medications used to treat pain and inflammation, but are not the primary target of ondansetron.

**Clinical Pearl / High-Yield Fact**
It's worth noting that ondansetron is also used to treat and prevent migraines, and its effectiveness in this context is thought to be related to its ability to block the release of serotonin and other neurotransmitters involved in the migraine pathway.

**✓ Correct Answer: D. 5 HT3 antagonist. Ondansetron acts as a selective 5-HT3 receptor antagonist.**